

FOI – 2341

1st May 2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

[a] Data on numbers of patients from the electronic prescribing system

BREAST CANCER

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	
1.2 Alpelisib (Piqray)	
1.3 Fulvestrant (fulvestrant or Faslodex)	
1.4 Palbociclib (Ibrance)	
1.5 Ribociclib (Kisqali)	

Q2. How many patients received abemaciclib (Verzenios) for **early breast cancer** in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Number patients treated

Q3. How many patients received abemaciclib (Verzenios) with the following treatment intent in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Treatment intent	Number patients treated
3.1 Curative	
3.2 Palliative	
3.3 Not known / stated	

Q4. How many patients were treated with the following medicines in combination with fulvestrant in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of combination or monotherapy	Number patients treated
4.1 Abemaciclib (Verzenios) + Fulvestrant (fulvestrant or Faslodex)	
4.2 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	
4.3 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	

Response:

This information cannot be retrieved from the Southern Trust Pharmacy Department.

The information you require may be held centrally by the Belfast Health & Social Care Trust.

You can contact them at:

Public Liaison
 Belfast HSC Trust
 1st Floor, Nore Villa
 Knockbracken Healthcare Park
 Belfast, BT8 8BH

Email: publicliaison@belfasttrust.hscni.net

[a] Data on numbers of patients from the electronic prescribing system

PROSTATE CANCER

Q5. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
5.1 Abiraterone (Zytiga or generic abiraterone)	
5.2 Apalutamide (Erleada)	
5.3 Cabazitaxel (Jevtana or generic cabazitaxel)	
5.4 Darolutamide (Nubeqa)	
5.5 Enzalutamide (Xtandi)	

Q6. How many patients were treated with docetaxel specifically for **prostate cancer** (ICD-10 code = C61) in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
Docetaxel	

Q7. How many patients were treated with the following medicine combinations in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
7.1 Abiraterone (Zytiga or abiraterone) + Androgen Deprivation Therapy	
7.2 Apalutamide (Erleada) + Androgen Deprivation Therapy	
7.3 Darolutamide (Nubeqa) + Docetaxel + ADT	
7.4 Enzalutamide (Zytiga) + Androgen Deprivation Therapy	

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

Response:

This information cannot be retrieved from the Southern Trust Pharmacy Department.

The information you require may be held centrally by the Belfast Health & Social Care Trust.

You can contact them at:

Public Liaison
Belfast HSC Trust
1st Floor, Nore Villa
Knockbracken Healthcare Park
Belfast, BT8 8BH

Email: publicliaison@belfasttrust.hscni.net

[a] Data on numbers of patients from the electronic prescribing system
OVARIAN and ENDOMETRIAL CANCERS

Q8. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of October 2023 and end of December 2023?

Please provide data for the latest 3-month period, if Oct to Dec 23 is not available

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	
8.2 Niraparib (Zejula)	
8.3 Rucaparib (Rubraca)	

Q9. How many patients were treated for **ovarian, fallopian tube or primary peritoneal cancers**, with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
9.1 Olaparib in total	
9.2 Olaparib monotherapy	
9.3 Olaparib + bevacizumab in combination	
9.4 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	

Q10. How many patients were treated for **endometrial cancer** with the following medicines as monotherapy or in combination, in the 3 months between the start of October 2023 and end of December 2023?

Name of medicine	Number patients treated
10.1 Dostarlimab monotherapy	
10.2 Dostarlimab + platinum-based chemotherapy, or dostarlimab + carboplatin and paclitaxel	

10.3 Pembrolizumab (Keytruda) in total	
10.4 Lenvatinib (Lenvima) in total	
10.5 Pembrolizumab monotherapy	
10.6 Pembrolizumab + Lenvatinib (Lenvima) in combination	

Response:

This information cannot be retrieved from the Southern Trust Pharmacy Department.

The information you require may be held centrally by the Belfast Health & Social Care Trust.

You can contact them at:

Public Liaison
Belfast HSC Trust
1st Floor, Nore Villa
Knockbracken Healthcare Park
Belfast, BT8 8BH

Email: publicliaison@belfasttrust.hscni.net

[b] data on usage of medicines from the hospital pharmacy system

Fields to include in the data extract from the hospital pharmacy database:

Field	
Calendar year	
Calendar month	
Name of Health Board / Trust	
Drug substance (INN name of drug)	
Drug product pack name	Virtual or actual product pack name
Quantity unit of measure (UOM)	e.g. tablet, mL, vial, the unit in which the quantity can be measured
Quantity issued	

Filters

- Time period: Jan 2019 to Feb 2024, or the latest available month
- Drugs to include:

- | | |
|---------------------------------------|--------------------------------------|
| 1. Abemaciclib (Verzenios) - | Please see attached pdf |
| 2. Apelisib (Piqray) - | NOT USED WITHIN SHSCT TO DATE |
| 3. Palbociclib (Ibrance)- | Please see attached pdf |
| 4. Ribociclib (Kisqali)- | Please see attached pdf |
| 5. Abiraterone (Zytiga, abiraterone)- | Please see attached pdf |
| 6. Apalutamide (Erleada) | NOT USED WITHIN SHSCT TO DATE |
| 7. Darolutamide (Nubeqa)- | Please see attached pdf |
| 8. Enzalutamide (Xtandi)- | Please see attached pdf |
| 9. Dostarlimab (Jemperli) | NOT USED WITHIN SHSCT TO DATE |
| 10. Niraparib (Zejula) | NOT USED WITHIN SHSCT TO DATE |
| 11. Olaparib (Lynparza)- | Please see attached pdf |
| 12. Rucaparib (Rubraca) | NOT USED WITHIN SHSCT TO DATE |

Email: foi.team@southerntrust.hscni.net